Most Read Articles
Jairia Dela Cruz, 14 Jan 2019
The potassium-competitive acid blocker vonoprazan demonstrates superior efficacy in the treatment of patients with erosive oesophagitis compared with the proton pump inhibitor lansoprazole, with the results of a small trial showing that the former more rapidly provides complete sustained heartburn relief during the first week of therapy.
01 Mar 2016
Bathing with 2% chlorhexidine gluconate-medicated washcloth is cost-effective for the prevention of central line-associated bloodstream infection (CLABSI), based on a systematic review and meta-analysis of four studies.
08 Jan 2019
Treatment with spironolactone has shown consistent, albeit modest, clinical effectiveness in older patients with heart failure with reduced ejection fraction (HFrEF) regardless of renal eligibility criteria used, a recent study has shown.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

DCV+SOF±RBV, VEL/SOF±RBV both effective against genotypes 2, 3 hepatitis C

01 Jan 2019

Treatment regimens containing daclatasvir plus sofosbuvir with or without ribavirin (DCV+SOF±RBV) and the velpatasvir–sofosbuvir combination with or without ribavirin (VEL/SOF±RBV) deliver comparable efficacies against genotypes 2 and 3 hepatitis C virus (HCV) infection, a new study has shown.

Researchers evaluated 44 and 256 patients with genotype 2 HCV who received DVC+SOF±RBV (mean age 62.5±7.0 years 100 percent male) and VEL/SOF±RBV (mean age 63.4±6.4 years; 98.4 percent male), respectively. A total of 514 and 455 genotype 3 HCV patients were also included and were given DCV+SOF±RBV (mean age 60.9±5.6 years; 98.2 percent male) and VEL/SOF±RBV (mean age 61.0±6.7 years; 97.1 percent male), respectively.

Data for sustained virologic response (SVR) were available for 2,774 genotype 2 patients. Among these, 93.9 percent achieved SVR, the rates of which were comparable among those who were given DCV+SOF±RBV (88.1 percent) and VEL/SOF+RBV (89.5 percent; p=1.00). The use of RBV did not lead to statistical improvements in SVR rates.

In comparison, SVR was reported in 90.2 percent of 2,626 genotype 3 patients, for whom the pertinent data were available. Rates were likewise comparable between DCV+SOF±RBV (88.1 percent) and VEL/SOF±RBV (86.4 percent; p=0.51) patients.

Multivariate models showed that a decompensated disease (odds ratio [OR], 0.68; 95 percent CI, 0.47–0.99; p=0.04) and prior HCV treatment (OR, 0.51; 0.36–0.72; p<0.001) significantly reduced the likelihood of SVR in genotype 3 patients. In those with genotype 2 disease, only age <55 years exerted this effect (OR, 0.45; 0.27–0.77; p=0.002).

“The results support current evidence-based guidelines for the use of either DCV+SOF or VEL/SOF as effective treatment options for genotypes 2 and 3,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 14 Jan 2019
The potassium-competitive acid blocker vonoprazan demonstrates superior efficacy in the treatment of patients with erosive oesophagitis compared with the proton pump inhibitor lansoprazole, with the results of a small trial showing that the former more rapidly provides complete sustained heartburn relief during the first week of therapy.
01 Mar 2016
Bathing with 2% chlorhexidine gluconate-medicated washcloth is cost-effective for the prevention of central line-associated bloodstream infection (CLABSI), based on a systematic review and meta-analysis of four studies.
08 Jan 2019
Treatment with spironolactone has shown consistent, albeit modest, clinical effectiveness in older patients with heart failure with reduced ejection fraction (HFrEF) regardless of renal eligibility criteria used, a recent study has shown.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.